News Coverage

News Coverage

HospiMedica: AI-Based Predictive Analytics Platform Receives FDA Emergency Use Authorization in Support of COVID-19 Patients

Developed by CLEW (Netanya, Israel), CLEW-ICU allows healthcare providers to use predictive screening information to help identify patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability. The AI-based algorithms are machine-learning models trained to identify respiratory failure and or hemodynamic instability hours in advance. This allows for additional evaluation and potentially early intervention, planning, resource management.

Read More »

ILTV: Interview with CLEW’s CEO, Gal Salomon

CLEW Receives FDA Emergency Use Authorization (EUA) for Its Predictive Analytics Platform in Support of COVID-19 Patients. CLEWICU is the only device authorized by the FDA to provide early identification of patients who are likely to experience respiratory failure or hemodynamic instability, both potentially common but significant complications associated with COVID-19.

Read More »

Like what you see? Drop us a line.